GlassScriptPhysician profile
Riley Guest
NPI 1033885256
$3,133.81
in general payments reported to CMS, 2019-2025
22 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $336 · 2024: $608 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319 · Travel and Lodging: $779 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.31 |
| Travel and Lodging | $778.50 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,215.41 | 2025 | Interstim |
| Sumitomo Pharma America, INC. | $385.60 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $265.87 | 2024-2025 | |
| Urogen Pharma, INC. | $191.15 | 2023-2024 | Jelmyto |
| Abbvie INC. | $187.80 | 2024-2025 | |
| Endo USA, INC. | $139.42 | 2024-2025 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $116.49 | 2024 | Aquabeam System |
| Progenics Pharmaceuticals, INC. | $96.90 | 2023-2024 | Pylarify |
| Janssen Biotech, INC. | $77.31 | 2023-2025 | Erleada |
| Antares Pharma, INC. | $75.19 | 2025 | Xyosted |
| Boston Scientific Corporation | $71.27 | 2025 | General - Kidney Stone Disease |
| Pfizer INC. | $65.59 | 2023-2025 | |
| Laborie Medical Technologies Corp. | $45.75 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Dendreon Pharmaceuticals LLC | $45.37 | 2024 | Provenge |
| Sun Pharmaceutical Industries INC. | $26.40 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $26.09 | 2025 | |
| Bluewind Medical | $20.99 | 2025 | Revi |
| Endo Pharmaceuticals INC. | $18.59 | 2024 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $16.57 | 2023 | Lynparza |
| Kowa Pharmaceuticals America, INC. | $16.50 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $16.04 | 2024 | Keytruda |
| Teleflex LLC | $13.51 | 2025 | Urolift |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riley Guest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.